Literature DB >> 1980839

MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells.

W G Tatton1, M M Kwan, M C Verrier, N A Seniuk, E Theriault.   

Abstract

To determine whether 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) alters the tyrosine hydroxylase (TH) immunoreactivity of murine dopaminergic retinal amacrine cells, 8-10-week-old C57BL/6J mice were treated with i.p. with saline or cumulative doses of MPTP ranging from 10 to 300 mg/kg. Paraformaldehyde-fixed retinal whole mounts and cross sections were examined using immunochemistry with a tyrosine hydroxylase (TH) or a choline acetyltransferase (ChAT) polyclonal antibody and an avidin-biotin peroxidase reaction. Both TH+ amacrines and ChAT+ retinal neurons showed somal and process morphology and distributions that were commensurate with previous studies of the same or several related species. At 20 days following the MPTP treatment, there was a loss of TH+ amacrines according to a logarithmic relationship relative to MPTP dosage. The loss ranged from 18 to 87% for the dosage range without any decrease in the numbers of ChAT+ neurons. The TH+ amacrines were deleted randomly from the retinas without any peripheral-central predilection. By 273 days after MPTP treatment, the number of TH+ amacrines had returned to values found for age-matched controls demonstrating that the loss of TH immunoreactivity was reversible and occurred without destruction of TH+ amacrines. Computer densitometry revealed that the MPTP-treated TH+ amacrines were divided into two distinct populations: one with normal TH immunodensity levels and a second with TH immunodensity levels below our detection capability. Increasing the MPTP dosage increased the proportion of TH amacrines in the second population. The transient and completely reversible disappearance in the number of TH+ amacrines: (1) appears to form the basis for the decreased concentrations of dopamine and the loss of catecholamine fluorescent neurons previously described for MPTP-treated mouse retinae; (2) may underlie the defects in the electroretinograms of MPTP-treated monkeys, and (3) may result as a response to neurite damage similarly to the alterations in protein synthesis in other central neurons following axonal damage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980839     DOI: 10.1016/0006-8993(90)91056-m

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  24 in total

1.  Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease.

Authors:  Ozgül Altintaş; Pervin Işeri; Berna Ozkan; Yusuf Cağlar
Journal:  Doc Ophthalmol       Date:  2007-10-26       Impact factor: 2.379

2.  Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  M Vila; V Jackson-Lewis; S Vukosavic; R Djaldetti; G Liberatore; D Offen; S J Korsmeyer; S Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

3.  Potential role of retina as a biomarker for progression of Parkinson's disease.

Authors:  Tian Tian; Xiao-Hua Zhu; Yun-Hai Liu
Journal:  Int J Ophthalmol       Date:  2011-08-18       Impact factor: 1.779

4.  Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress.

Authors:  Raymond H Kim; Patrice D Smith; Hossein Aleyasin; Shawn Hayley; Matthew P Mount; Scott Pownall; Andrew Wakeham; Annick J You-Ten; Suneil K Kalia; Patrick Horne; David Westaway; Andres M Lozano; Hymie Anisman; David S Park; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-22       Impact factor: 11.205

5.  Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

Authors:  William Dauer; Nikolai Kholodilov; Miquel Vila; Anne-Cecile Trillat; Rose Goodchild; Kristin E Larsen; Roland Staal; Kim Tieu; Yvonne Schmitz; Chao Annie Yuan; Marcelo Rocha; Vernice Jackson-Lewis; Steven Hersch; David Sulzer; Serge Przedborski; Robert Burke; Rene Hen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-10       Impact factor: 11.205

6.  Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse model.

Authors:  Xu Zhang; Jian-Ying Zhou; Mark H Chin; Athena A Schepmoes; Vladislav A Petyuk; Karl K Weitz; Brianne O Petritis; Matthew E Monroe; David G Camp; Stephen A Wood; William P Melega; Diana J Bigelow; Desmond J Smith; Wei-Jun Qian; Richard D Smith
Journal:  J Proteome Res       Date:  2010-03-05       Impact factor: 4.466

7.  Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: Implications for visual manifestations of Parkinson's disease.

Authors:  Shounak Baksi; Ajai K Tripathi; Neena Singh
Journal:  Free Radic Biol Med       Date:  2016-06-23       Impact factor: 7.376

8.  Stress accelerates neural degeneration and exaggerates motor symptoms in a rat model of Parkinson's disease.

Authors:  Lori K Smith; Nafisa M Jadavji; Keri L Colwell; S Katrina Perehudoff; Gerlinde A Metz
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

9.  DNER and NFIA are expressed by developing and mature AII amacrine cells in the mouse retina.

Authors:  Patrick W Keeley; Benjamin E Reese
Journal:  J Comp Neurol       Date:  2017-11-11       Impact factor: 3.215

10.  Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein.

Authors:  Matthew Benskey; Ki Yong Lee; Kevin Parikh; Keith J Lookingland; John L Goudreau
Journal:  Neurotoxicology       Date:  2013-05-01       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.